Polifarma Offers Hope for Intensive Care Patients with 100 Thousand Ampoule Drugs Produced For Covid-19
Engaging in production in Turkey’s health sector for 34 years, the local and national pharmaceutical company Polifarma has started to produce the drug, recognized by all authorities worldwide including FDA (U.S. Food and Drug Administration) and whose positive effect in coronavirus treatment has been announced by the Ministry of Health, with an exclusive permission for the treatment of the intensive care patients who cannot be fed orally. Polifarma will donate 100 thousand ampoules produced in I.V. form for vascular use to the Ministry of Health. The drug is expected to offer hope for 10 thousand intensive care patients.
Polifarma Ilac, with 100 percent domestic capital, has made a critical move towards the treatment of the coronavirus (Covid – 19) outbreak and started to produce a drug, which has been recognized by all authorities worldwide including FDA (U.S. Food and Drug Administration) and whose positive result against Covid – 19 has been announced by the Ministry of Health. Polifarma has completed the production of the drug in I.V. form, which will offer hope for the treatment of intensive care patients who cannot be fed orally, and has made a license application to the Ministry of Health. A total of 100 thousand drugs, to be sufficiently produced for the treatment of 10 thousand intensive care patients, will be donated to the Ministry of Health by Polifarma.
Increasing the efforts at its production facility right after the emergence of the first coronavirus case in Turkey and raising its capacity to 120%, Polifarma has taken a step towards the production of the drug, whose benefit against coronavirus has been observed in clinical trials.
100 thousand ampoules will be donated to Ministry of Health
Vildan Kumrulu, Polifarma’s Vice Chairman of the Board, said: “We started to seek a solution by asking ‘What can we do as Polifarma’ against this pandemic that affects our country and the whole world. Within this scope, we took a quick step to produce the drug, which is the primary treatment in the treatment protocols of the Ministry of Health, for intensive care patients who cannot be fed orally, in other words, who cannot use any drug in tablet form. In this challenging process, we managed to bring the highest quality raw materials to our country by contacting suppliers from all over the world. We have subsequently completed the production of 100 thousand ampoules with the exclusive permission of the Turkey Pharmaceuticals and Medical Devices Agency (TMMDA). As Polifarma, our biggest dream is a healthy Turkey; and in this context, we will donate 100 thousand ampoules to the Ministry of Health. Whenever our Ministry of Health requests from us, we will send our products. We have a sufficient production capacity to meet new production demands. After completing raw material supplies, we will start the production of another drug declared by our Ministry of Health for treatment protocols, on April 20.
”We are at the service of all doctors and healthcare professionals”
Underlining that they are always proud of being local and national, Kumrulu stated, “We have always worked considering the interests of our country in this journey that we started with the love of our country. We could not be indifferent to the situation in our country. Today, we are at the service of all doctors and healthcare professionals working at the cost of their lives. Our only wish is that all humanity will overcome this pandemic with minimal damage”.
About Polifarma Ilac:
Turkey's most preferred brand in the field of hospital drugs and serum, Polifarma Ilac is a pharmaceutical company with 100% domestic capital and a 34-year history in IV (vascular access) drug and serum production. Pharmacist Necdet Nuri Kumrulu, who founded Aroma Ilac in 1983, purchased Polifarma Ilac in 1986 and continued his operations under the same name. As Turkey’s industry leader in the field of serum, Polifarma continues its operations in its facility located on a land of 77 thousand square meters, which has an annual production capacity of 250 million boxes. With the capability of manufacturing products in both Glass/PVC and PP forms at the same time, Polifarma has 465 licensed products in all forms in 11 different therapeutic areas. Having developed Turkey's first lipid product and produced the first 3-chamber paranteral nutrition solution and SAPD device in the field of peritoneal dialysis in line with its innovative and modern approach, Polifarma represents Turkey in the global market. Polifarma continues to grow with the vision of becoming a global leader in 2025.